Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients

Vaccine

Volumn 27, Issue 1, 2009, Pages 17-22

  Cruciani, Mario ^a   Mengoli, Carlo ^b   Serpelloni, Giovanni ^a   Lanza, Andrea ^a   Gomma, Maurizio ^a   Nardi, Stefano ^a   Rimondo, Claudia ^a   Bricolo, Francesco ^a   Consolaro, Sandro ^c   Trevisan, MariaTeresa ^c   Bosco, Oliviero ^a  

^a Center of Preventive Medicine   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c G Fracastoro Hospital   (Italy)

Author keywords

Hepatitis B vaccination; HIV 1; Revaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION; VIRUS LOAD;

ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TIME FACTORS;

EID: 57049153416     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.040     Document Type: Article

References (20)

1. Centers for Disease Control & Prevention Recommendations of the advisory committee on immunization practices (ACIP): use of vaccines and immune globulins in person with altered immunocompetence. MMWR Morb Mort Wkly Rep 1993; 42 (RR4):1-18.
2. Kellerman S.E., Hanson D.L., McNaghten A.D., and Fleming P.L. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 188 (2003) 571-577
3. Laurence J.C. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 118 (2005) 75S-83S
4. Tedaldi E.M., Baker R.K., Moorman A.C., Wood K.C., Fuhrer J., McCabe R.E., et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 38 (2004) 1478-1484
5. Kahn J. Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Clin Infect Dis 35 (2002) 1382-1387
6. Collier A.C., Corey L., Murphy V.L., and Handsfield H.H. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 109 (1988) 101-105
7. Zuin G., Principi N., Tornaghi R., Paccagnini S., Re M., Massironi E., et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 10 (1992) 857-860
8. Rosman A.S., Basu P., Galvin K., and Lieber C.S. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 103 (1997) 217-222
9. Lao-araya M., Puthanakit T., Aurpibul L., Sirisanthana T., and Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 25 (2007) 5324-5329
10. Cruciani M., Mengoli C., Serpelloni G., Mazzi R., Bosco O., and Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 25 (2007) 709-718
11. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 55 December (RR-16) (2006) 1-33 Erratum in: MMWR Morb Mortal Wkly Rep 2007 October 26;56(42):1114
12. Fonseca M.O., Pang L.W., de Paula Cavalheiro N., Barone A.A., and Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 23 (2005) 2902-2908
13. Das Gracas Sasaki M., Foccacia R., and de Messias-Reason I.J. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection et al. Vaccine 21 (2003) 4545-4549
14. Cornejo-Juárez P., Volkow-Fernández P., Escobedo-López K., Vilar-Compte D., Ruiz-Palacios G., and Soto-Ramírez L.E. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 3 (2006) 9
15. Cooper C.L., Angel J.B., Seguin I., Davis H.L., and Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46 (2008) 1310-1314
16. Pasricha N., Datta U., Chawla Y., Singh S., Arora S.K., Sud A., et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis 6 (2006) 65
17. Rey D., Krantz V., Partisani M., Schmitt M.P., Meyer P., Libbrecht E., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18 (2000) 1161-1165
18. de Vries-Sluijs T.E., Hansen B.E., van Doornum G.J., Springeling T., Evertsz N.M., de Man R.A., et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 197 (2008) 292-294
19. Van Herck K., Van Damme P., Thoelen S., and Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine 16 (1998) 1933-1935
20. Gabbuti A., Romanò L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 25 (2007) 3129-3132